The biopharma industry has a well-established rule: launch trajectory is set early, and it rarely changes.
Studies from McKinsey, IQVIA, and Veeva consistently show that 80–85% of products³ lock in their long-term performance within the first six months after launch. Early perceptions among HCPs harden quickly. Access patterns become entrenched. Market behaviors stabilize.
If adoption falters early due to inconsistent messaging, low confidence among reps, or misalignment between training and content, the downstream effect can be devastating.
Emerging biopharma companies must approach launch readiness with the same intensity and discipline that they apply to Phase III trials. There is no warm-up period. The field force must be fully equipped—scientifically fluent, compliant, confident, and consistent from the very first HCP interaction.
That is why launch readiness must be systematic, integrated, and accelerated.
